What the Valsartan Lawsuits Are About
Valsartan lawsuits center on contamination of the blood-pressure medication valsartan with N-nitrosodimethylamine, or NDMA, a probable human carcinogen. The U.S. Food and Drug Administration began issuing recalls in July 2018 after detecting NDMA in products manufactured by certain Chinese and Indian facilities. The lawsuits claim patients were exposed to a potentially cancer-causing impurity for years without adequate warning, and they seek compensation for medical monitoring, injury and other damages.
More from this site
Keep reading the latest coverage
Most cases have been consolidated in federal court under a multidistrict litigation docket, where judges are managing discovery and bellwether trials. The core question in the valsartan lawsuits is whether the contamination was foreseeable, whether drugmakers and distributors should have caught it earlier, and what injuries the exposure actually caused.
Which Companies and Products Are Named
The valsartan lawsuits name a range of defendants, including the generic manufacturers that produced the recalled tablets, the Indian and Chinese facilities that supplied the active pharmaceutical ingredient, and the major distributors that moved the drugs through the supply chain. Brand-name valsartan products from Novartis were not part of the recall, but many generic versions from companies including Major Pharmaceuticals, Solco Healthcare, Teva Pharmaceuticals and others were pulled from pharmacy shelves.
Plaintiffs in the valsartan lawsuits typically argue that the companies failed to conduct adequate testing of the raw ingredients, ignored warning signs from foreign regulators, and did not issue timely recalls. The FDA's investigation identified specific manufacturing changes at the Zhejiang Huahai Pharmaceuticals facility in China as a likely source of the NDMA impurity.
Health Risks and the Science Behind the Concerns
NDMA is classified as a probable human carcinogen based on animal studies, and long-term exposure to contaminated valsartan could theoretically increase the risk of certain cancers, including liver, kidney and gastric tumors. However, the actual risk to any individual patient depends on the level of contamination, the duration of exposure and personal health factors.
Regulatory agencies worldwide set acceptable daily intake limits for NDMA, and the valsartan recalls were triggered when tests showed levels above those limits. The valsartan lawsuits rely on toxicology experts to establish exposure timelines and on medical records to link any diagnosed cancers to the contaminated medication. Because cancer can take years to develop and has many causes, establishing a direct causal link in court is scientifically complex.
Where the Litigation Stands Now
As of mid-2025, the valsartan multidistrict litigation continues in the U.S. District Court for the District of New Jersey. Hundreds of individual cases have been filed, and the court has been conducting discovery, motion practice and early settlement discussions. Bellwether trials are expected to help both sides gauge how juries respond to the evidence on contamination, corporate knowledge and injury causation.
Some valsartan lawsuits have resulted in settlements, though the terms are often confidential. Other cases are still working through the legal process, and new filings are possible as more patients come forward with a cancer diagnosis after long-term valsartan use. The pace of the litigation depends on court schedules, the availability of expert witnesses and the willingness of defendants to negotiate.
What Affected Patients Can Do
Patients who took recalled valsartan and later received a cancer diagnosis may be eligible to join the multidistrict litigation or to file an individual claim. Key steps include keeping all medical records, preserving the prescription bottles or packaging, noting the manufacturer and lot number if available, and consulting a lawyer who handles pharmaceutical injury cases. Statutes of limitations vary by state, so timing matters.
For patients who took valsartan but have not been diagnosed with cancer, the practical advice is different. The valsartan lawsuits primarily target cancer injuries, but some claimants have raised claims for the cost of switching medications, the anxiety of potential exposure and other economic and noneconomic harms. Anyone concerned about their exposure should talk to a physician about their personal risk and to a qualified attorney about their legal options.